Serum ADMA levels and carotid intima media thickness (CIMT) were measured in patients and controls.Results: Lower serum ADMA levels and higher CIMT measurements were observed in the patient group than in the control group (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objective: This study aimed to make an early diagnosis of endothelial dysfunction, the initial pathology of atherosclerosis in metabolic syndrome (MS) patients, and to investigate the usefulness of serum asymmetric dimethylarginine (ADMA) levels as a marker of cardiovascular risk.Methods: Thirty-eight patients (24 women and 14 men) who were diagnosed with MS, according to the National Cholesterol Education Program Adult Treatment Panel III, were included in the study.
📊
Key Findings & Data:The control group comprised 25 and 12 healthy women and men, respectively; with similar age profiles.
💡
Conclusion & Impact:Serum ADMA levels and carotid intima media thickness (CIMT) were measured in patients and controls.Results: Lower serum ADMA levels and higher CIMT measurements were observed in the patient group than in the control group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Objective: This study aimed to make an early diagnosis of endothelial dysfunction, the initial pathology of atherosclerosis in metabolic syndrome (MS) patients, and to investigate the usefulness of serum asymmetric dimethylarginine (ADMA) levels as a marker of cardiovascular risk.Methods: Thirty-eight patients (24 women and 14 men) who were diagnosed with MS, according to the National Cholesterol Education Program Adult Treatment Panel III, were included in the study. Patients with a history of systemic diseases, except components of MS, and smokers were excluded from the study. The control group comprised 25 and 12 healthy women and men, respectively; with similar age profiles. Serum ADMA levels and carotid intima media thickness (CIMT) were measured in patients and controls.Results: Lower serum ADMA levels and higher CIMT measurements were observed in the patient group than in the control group (p
🔖
Cite This Article
KISAKOL, G., ARICI, S., KAPUCİ, A., KIYICI, S. (2022). Asymmetric Dimethylarginine Level as an Indicator for Cardiovascular Risk in Patients with Metabolic Syndrome. European Archives of Medical Research, Cilt: 36 - Sayı: 3, 172–177. https://ajindex.com/articles/650413
Gören B, Fen T. The Metabolic Syndrome: Review. Türkiye Klinikleri J Med Sci 2008;28:686-96.
Işıldak M, Sain Güven G, Gürlek A: Metabolik Sendrom ve İnsülin Direnci. Hacettepe Tıp dergisi 2004;35:96-9. Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 2000;10:665-79.
Kung AWC, Pang RWC, Janus ED. Elevated serum lipoprotein(a) in subclinical hypothyroidism. Clinic Endocrinology 1995;43:445-9.
Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DE, et al. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006;184:383-8.
Altekin ER, Demir İ, Başarıcı İ, Yılmaz H: Karotis intima-media kalınlığının anjiyografik koroner arter hastalığı varlığı ve yaygınlığı ile ilişkisi. Türk Kardiyol Dern Ars 2007;35:90-6.
Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O et al. Assymetric dimethyl arginine (ADMA): a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998;98:1842-7. Cooke JP. ADMA: its role in vascular disease. Vasc Med 2005;10:11-7.
Altinova AE, Arslan M, Sepici-Dincel A, Akturk M, Altan N, Toruner FB. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab 2007;92:1881-5.
Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004;27:765-9.
Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ et al. Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community. Circulation 2009;119:1592-600. Päivä H, Lehtimäki T, Laakso J, Ruokonen I, Rantalaiho V, Wirta O, et al. Plasma concentrations of asymmetric-dimethylarginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003;52:303-7.
Onat A, Köroğlu B, Can G, Karagöz A, Yüksel M, Aydın M. Apparently “low” serum asymmetric dimethylarginine is associated with fasting glucose and tends toward association with type-2 diabetes. Anadolu Kardiyol Derg 2014;14:26-33.
Xiong Y, Fu YF, Fu SH, Zhou HH. Elevated levels of the serum endogenous inhi